Jean-Marc Taymans is a bioengineer from the KU Leuven (Belgium). After working as a vaccine process engineer at SmithKline-Beecham Biologicals, he began his doctoral research via the Free University of Amsterdam in the research labs of Johnson & Johnson Pharmaceutical Research and Development. In 2004, Dr. Taymans joined KU Leuven to study the molecular pathogenesis of Parkinson’s disease (PD) genes. After a Fulbright scholarship at the National Institutes of Health, he joined the UMR-S 1172 research center in Lille (France), a mixed Inserm – Université de Lille – Lille University Hospital center, to further study cell signaling processes in PD while integrating clinical translation of experimental findings from patient biosamples. With a strong focus on LRRK2, Dr. Taymans’s research uses a multidisciplinary approach, from biochemical analysis and cellular models to validation in preclinical models, and has produced more than 45 publications.
Exploring the Use of Molecules that Stabilize the Interaction between LRRK2 Kinase and the 14-3-3 Adapter Protein as a Neuroprotective Therapy for Parkinson’s Disease
Rab Detection Initiative and LRRK2 Detection Initiative Supplemental Support RDI, and LCC exosome replication